Group 1: Business Performance and Revenue - In 2024, the company achieved sales revenue of CNY 58,804.95 million for contrast agents, a year-on-year increase of 9.87% [1] - Sales revenue for hypoglycemic products reached CNY 12,598.34 million, growing by 33.24% year-on-year [1] - The company reported a decline in raw material sales revenue to CNY 9,003.14 million, down by 20.83% [1] - Sales revenue for traditional Chinese medicine preparations was CNY 16,844.68 million, reflecting a year-on-year growth of 19.65% [1] - The company’s overseas revenue for 2024 was CNY 13,216.14 million, marking a 15.02% increase [4] Group 2: Strategic Developments - The company continues to implement a "chemical + traditional Chinese medicine" dual-driven strategy, focusing on contrast agents, hypoglycemic drugs, and central nervous system traditional Chinese medicine [1] - The construction of the Cangzhou Phase III raw material production project has been completed, enhancing the production capacity for gadolinium and iodine contrast agents [2] - The Bozhou production base is progressing, with the first phase expected to start trial production and process validation within the year [3] Group 3: Market Expansion and Product Development - The company is expanding its market presence internationally, with successful exports of contrast agents and raw materials to South America, Africa, and Asia [4] - The company’s subsidiary, Haichang Pharmaceutical, is one of the few domestic producers with iodine contrast agent production qualifications, with an annual capacity of 1,000 tons [2] - The "MERCURY non-invasive blood test" technology developed by the affiliated company, Shihe Gene, allows for the screening of nine types of cancer from a single blood sample [7]

Financial Performance - In Q1 2025, the company achieved revenue of 282.68 million CNY, a year-on-year increase of 36.23% [1] - Net profit attributable to shareholders was 14.54 million CNY, up 26.13% year-on-year [1] - Net profit excluding non-recurring items reached 13.09 million CNY, reflecting a 14.34% increase year-on-year [1] Growth Drivers - The chemical generic drug segment capitalized on national procurement policies, expanding market share and sales [1] - The traditional Chinese medicine segment achieved rapid integration and expansion through acquisitions, enhancing product pipelines [2] - International market expansion has shown results, with continuous growth in export business [2] Market Strategy - The company aims to increase domestic market share while actively participating in procurement and promoting other products [3] - New product development and market entry will be accelerated to enhance competitiveness [3] - The company will leverage EU GMP and Brazil GMP certifications to boost international market contributions [3] Acquisition Progress - The integration of Tianyuan Pharmaceutical is progressing smoothly across production, marketing, finance, and supply chain management [4] - The company is focusing on fine management and sustainable development of Tianyuan Pharmaceutical [4] Overseas Revenue - In the reporting period, overseas revenue reached 132.16 million CNY, a year-on-year increase of 15.02% [6] - The company successfully exported contrast agents and raw materials to markets in South America, Africa, and Asia [5] R&D Developments - R&D investment for the period was 69.24 million CNY, a decrease of 43.40% year-on-year due to a stabilization phase in project initiation [7] - The company has 12 projects under review and 23 new projects initiated, totaling 35 projects [7] - Recent approvals include various formulations and specifications for contrast agents and other medications [7] Production Base Development - The construction of the Bozhou production base is progressing, with the first phase expected to begin trial production within the year [8] - The base will enhance production capacity for various dosage forms, supporting future strategic expansions in traditional and chemical medicine [8]